Eton Pharmaceuticals (ETON) Proxy Filing summary

Executive summary

• The annual meeting is scheduled for June 10, 2025, to be held virtually, with voting available online, by phone, mail, or live during the meeting.

• Shareholders will vote on the election of one director and the ratification of the independent auditor, with no other business currently anticipated.

• Proxy materials and the 2024 Annual Report are available online, and shareholders are encouraged to review risk factors and forward-looking statements.

Voting matters and shareholder proposals

• Shareholders will vote to elect Paul V. Maier as Class I director for a term ending in 2028.

• Ratification of Crowe LLP as the independent registered public accounting firm for fiscal year 2025 is on the agenda.

• No other proposals or business are expected at the meeting.

• Shareholder proposals for the 2026 meeting must be submitted between February 10 and March 12, 2026.

Board of directors and corporate governance

• The board consists of five members divided into three staggered classes, with a majority being independent.

• Board committees include audit, compensation, and nominating/governance, all composed of independent directors.

• The chairman and CEO roles are separated to enhance governance and oversight.

• Directors bring diverse experience in pharmaceuticals, finance, and governance, and are expected to attend and participate actively in meetings.

• The company maintains a Code of Business Conduct and Ethics for all directors, officers, and employees.